June 18, 2018
1 min read

FDA approves iDESIGN Refractive Studio for LASIK

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Johnson & Johnson Vision’s iDESIGN Refractive Studio LASIK platform has been approved by the FDA, according to a press release.

The iDESIGN, which uses topography-integrated, wavefront-guided technology, allows physicians to take precise measurements of both the inside and outside of the eye to personalize the LASIK procedure to each patient, the release said.

It has been approved for myopia, hyperopia and mixed astigmatism, and is the only LASIK platform for monovision LASIK in presbyopic myopia.

“The new iDESIGN Refractive Studio provides surgeons with the ability to deliver one-of-a-kind custom laser vision correction for each patient to have excellent visual outcomes following their LASIK procedure,” Jonathan Talamo, MD, chief medical officer and worldwide vice president of medical and clinical affairs at Johnson & Johnson Vision, said in the release.

The platform is expected to be commercially available in the third quarter of this year.